Jun13296
Jun13296 is an orally active quinoline SARS-CoV-2 papain-like protease inhibitor (IC50 = 0.13 µM, Ki = 8.8 nM). Jun13296 exhibits potent inhibition against SARS-CoV-2 variants and Nirmatrelvir -resistant mutants. Jun13296 improves lung viral titers, and prevents lung tissue damage in a SARS-CoV-2 infection model[1].
Product Specifications
CAS Number
3063566-68-4
UNSPSC
12352211
Target
SARS-CoV; Virus Protease
Related Pathways
Anti-infection
Field of Research
Infection
Smiles
O=C(N[C@@H](C1=CC(C2=CN(C)N=C2)=NC3=CC=CC=C13)C)C4=CC(N5C[C@@](N6C)([H])CC[C@@]6([H])C5)=CC=C4C
Molecular Formula
C30H34N6O
Molecular Weight
494.63
References & Citations
[1]Jadhav P, et al. Design of quinoline SARS-CoV-2 papain-like protease inhibitors as oral antiviral drug candidates. Nat Commun. 2025 Feb 13;16 (1) :1604.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
CSB-YP365878EFA-01 20 µg
Recombinant Epstein-Barr virus Epstein-Barr nuclear antigen 1 (EBNA1), partial
Sign In for Pricing
View Details CSB-YP365878EFA-02 100 µg
Recombinant Epstein-Barr virus Epstein-Barr nuclear antigen 1 (EBNA1), partial
Sign In for Pricing
View Details CSB-YP365878EFA-03 1 mg
Recombinant Epstein-Barr virus Epstein-Barr nuclear antigen 1 (EBNA1), partial
Sign In for Pricing
View Details 